Questions remain among top Food and Drug Administration officials over who has the appropriate legal authority to sign off on ...
2don MSN
Legal questions swirl around FDA's new expedited drug program, including who should give sign off
The Food and Drug Administration commissioner's effort to drastically shorten the review of drugs favored by President Donald ...
Stocktwits on MSN
Travere Therapeutics stock slumps after FDA extends drug review timeline to April: Retail is divided on eventual approval
The timeline extension comes on the heels of the FDA requesting additional information to assess Filspari’s clinical benefit.
By the end of March, the agency could approve multiple “national priority” voucher winners, as well as a gene therapy it ...
Travere Therapeutics recently reported that the FDA has extended its review of the supplemental New Drug Application for ...
Detailed price information for Travere Therapeutics Inc (TVTX-Q) from The Globe and Mail including charting and trades.
A new study co-written by a University of Illinois Urbana-Champaign expert in operations management finds that drugs approved ...
FDA delays drug reviews for two priority voucher drugs amid safety and efficacy concerns, extending timelines for Sanofi and Disc Medicine products.
A Type B meeting between the FDA and Plus Therapeutics offered clarity and direction for the next steps in development of ...
The FDA has handed out the first nine national priority vouchers, positioning companies including Merck KGaA, Regeneron and Sanofi to complete the approval process in one to two months. FDA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback